153 related articles for article (PubMed ID: 36374798)
21. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
[TBL] [Abstract][Full Text] [Related]
22. Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression.
Rong W; Wan N; Zheng X; Shi G; Jiang C; Pan K; Gao M; Yin Z; Gao ZJ; Zhang J
Phytomedicine; 2022 Jan; 95():153867. PubMed ID: 34923234
[TBL] [Abstract][Full Text] [Related]
23. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
24. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
25. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
[TBL] [Abstract][Full Text] [Related]
26. miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.
Xi J; Huang Q; Wang L; Ma X; Deng Q; Kumar M; Zhou Z; Li L; Zeng Z; Young KH; Zhang M; Li Y
Oncogene; 2018 Jun; 37(23):3151-3165. PubMed ID: 29540832
[TBL] [Abstract][Full Text] [Related]
27. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody.
Lee EJ; Jang GY; Lee SE; Lee JW; Han HD; Park YM; Kang TH
Immunol Lett; 2021 Dec; 240():137-148. PubMed ID: 34710507
[TBL] [Abstract][Full Text] [Related]
28. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
29. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
30. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
Chen Z; Chen Y; Peng L; Wang X; Tang N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028694
[TBL] [Abstract][Full Text] [Related]
31. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma.
Liu C; Miao X; Wang Y; Wen L; Cheng X; Kong D; Zhao P; Song D; Wang X; Ding X; Xia H; Wang W; Sun Q; Gong W
Cancer Sci; 2020 Oct; 111(10):3503-3515. PubMed ID: 32726482
[TBL] [Abstract][Full Text] [Related]
32. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
33. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
35. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.
Ke M; Zhang Z; Xu B; Zhao S; Ding Y; Wu X; Wu R; Lv Y; Dong J
Int Immunopharmacol; 2019 Oct; 75():105824. PubMed ID: 31437792
[TBL] [Abstract][Full Text] [Related]
36. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.
Deng H; Kan A; Lyu N; He M; Huang X; Qiao S; Li S; Lu W; Xie Q; Chen H; Lai J; Chen Q; Jiang X; Liu S; Zhang Z; Zhao M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168004
[TBL] [Abstract][Full Text] [Related]
37. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
38. Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma.
Atwa SM; Handoussa H; Hosny KM; Odenthal M; El Tayebi HM
World J Hepatol; 2020 Dec; 12(12):1211-1227. PubMed ID: 33442449
[TBL] [Abstract][Full Text] [Related]
39. Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-κB pathway.
Liu Z; Zhao L; Liu H; Dong N; Zhou N; Zhang Y; Yin T; He H; Gou J; Tang X; Yang L; Gao S
Int J Pharm; 2022 Nov; 628():122361. PubMed ID: 36332828
[TBL] [Abstract][Full Text] [Related]
40. Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling.
Li Z; Gao WQ; Wang P; Wang TQ; Xu WC; Zhu XY; Liu H
Curr Cancer Drug Targets; 2020; 20(11):868-874. PubMed ID: 32748749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]